Last updated: 2026-09-06 10:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alumis Inc. (ALMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11,12, with a market capitalization of $1,34B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,76 to $31,35. This page covers its latest market performance, valuation, price trends and company information.
$1,34B | |
$11,23 | |
$31,35 | |
$2,76 | |
$11,36 | |
2,74M | |
-- | |
-- | |
$31,35 | |
$3,76 | |
-- | |
-- |
Alumis Inc. (ALMS) last closed at $11,36 as of 2026-09-04 23:36:00, unchanged from the previous close of $11,36.
During the latest regular trading session, ALMS traded between $2,76 and $31,35, with a volume of 2,74M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Alumis Inc. (ALMS) moved from $22,29 to $11,12, representing a decline of 50,10% ($11,17).
The stock traded between $11,03 and $11,58 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7,42 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 26,7%
ALMS is currently trading at $11,12, placing it 26,7% of the way from its 52-week low of $3,76 to its 52-week high of $31,35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 239 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alumis Inc. (ALMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.